EDMONTON, Jan. 28 /CNW/ - Quest PharmaTech Inc. ("Quest" or the
"Company") today announced that it has signed a collaborative research
agreement with the BC Cancer Agency (the "BCCA") to develop a combination
therapy for the treatment of lung cancer. The potential treatment will utilize
the Company's lead oncology product, SL052, with various immunotherapeutic
agents. Research has shown that photodynamic therapy (PDT) can augment the
therapeutic effects of immunomodulators such as antibodies, antigens,
cytokines and immunoadjuvants in cancer patients.
